154 related articles for article (PubMed ID: 11434385)
41. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
Wang W; Zhang HT; Yang XL
J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
[TBL] [Abstract][Full Text] [Related]
42. Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer.
Singh RD; Nilayangode H; Patel JB; Shah FD; Shukla SN; Shah PM; Patel PS
Int J Biol Markers; 2011; 26(1):27-36. PubMed ID: 21337314
[TBL] [Abstract][Full Text] [Related]
43. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
44. Matrix Metalloproteinases and Their Tissue Inhibitors: an Evaluation of Novel Biomarkers in ANCA-Associated Vasculitis.
Zakiyanov O; Chocová Z; Hrušková Z; Hladinová Z; Kalousová M; Maličková K; Vachek J; Wurmová P; Kříha V; Zima T; Tesař V
Folia Biol (Praha); 2019; 65(5-6):227-236. PubMed ID: 32362306
[TBL] [Abstract][Full Text] [Related]
45. Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model.
Li X; Lu Y; Sun Y; Zhang Q
Int J Clin Exp Pathol; 2015; 8(6):7247-53. PubMed ID: 26261622
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
Papadopoulos DP; Moyssakis I; Makris TK; Poulakou M; Stavroulakis G; Perrea D; Votteas VE
Eur Cytokine Netw; 2005 Jun; 16(2):152-60. PubMed ID: 15941687
[TBL] [Abstract][Full Text] [Related]
47. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
[TBL] [Abstract][Full Text] [Related]
48. Abnormal circulating levels of matrix metalloproteinases and their inhibitors in diabetes mellitus.
Zayani Y; Allal-Elasmi M; Jacob MP; Zidi W; Ftouhi B; Feki M; Slimane H; Kaabachi N
Clin Lab; 2012; 58(7-8):779-85. PubMed ID: 22997979
[TBL] [Abstract][Full Text] [Related]
49. Effects of choline treatment in concentrations of serum matrix metalloproteinases (MMPs), MMP tissue inhibitors (TIMPs) and immunoglobulins in an experimental model of canine sepsis.
Kocaturk M; Eralp-Inan O; Tvarijonaviciute A; Cansev M; Ozyigit MO; Ceron JJ; Yilmaz Z; Kahraman MM
Vet Immunol Immunopathol; 2016 Nov; 180():9-14. PubMed ID: 27692098
[TBL] [Abstract][Full Text] [Related]
50. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
[TBL] [Abstract][Full Text] [Related]
51. Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with HIV-1 infection and syphilis or neurosyphilis.
Tsai HC; Ye SY; Kunin CM; Lee SS; Wann SR; Tai MH; Shi MH; Liu YC; Chen YS
Cytokine; 2011 May; 54(2):109-16. PubMed ID: 21354815
[TBL] [Abstract][Full Text] [Related]
52. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
[TBL] [Abstract][Full Text] [Related]
53. Matrix metalloproteinase levels in chronic thoracic aortic dissection.
Zhang X; Wu D; Choi JC; Minard CG; Hou X; Coselli JS; Shen YH; LeMaire SA
J Surg Res; 2014 Jun; 189(2):348-58. PubMed ID: 24746253
[TBL] [Abstract][Full Text] [Related]
54. Alterations in serum MMP and TIMP concentrations following chronic heroin abuse.
Kovatsi L; Batzios S; Nikolaou K; Fragou D; Njau S; Tsatsakis A; Karakiulakis G; Papakonstantinou E
Toxicol Mech Methods; 2013 Jun; 23(5):377-81. PubMed ID: 23256456
[TBL] [Abstract][Full Text] [Related]
55. Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure.
Täger T; Wiebalck C; Fröhlich H; Corletto A; Katus HA; Frankenstein L
Clin Res Cardiol; 2017 Dec; 106(12):974-985. PubMed ID: 28779229
[TBL] [Abstract][Full Text] [Related]
56. Role of matrix metalloproteinases in coronary artery disease.
Shah VK; Shalia KK; Mashru MR; Soneji SL; Abraham A; Kudalkar KV; Vasvani JB; Sanghavi ST
Indian Heart J; 2009; 61(1):44-50. PubMed ID: 19729688
[TBL] [Abstract][Full Text] [Related]
57. Differential expression profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases in females with or without pelvic organ prolapse.
Wang X; Li Y; Chen J; Guo X; Guan H; Li C
Mol Med Rep; 2014 Oct; 10(4):2004-8. PubMed ID: 25110112
[TBL] [Abstract][Full Text] [Related]
58. The role of plasma lipids in carotid bifurcation atherosclerosis.
Ford CS; Crouse JR; Howard G; Toole JF; Ball MR; Frye J
Ann Neurol; 1985 Mar; 17(3):301-3. PubMed ID: 3994317
[TBL] [Abstract][Full Text] [Related]
59. Differences in plasma MMPs and TIMPs protein expression and chemotherapy response in patients with tobacco- or wood-smoke-induced lung cancer.
Gonzalez-Avila G; Delgado J; Mendoza-Posada DA; Sommer B; Ramos C; Aquino-Galvez A; Camacho C
Respiration; 2013; 85(4):281-8. PubMed ID: 22441380
[TBL] [Abstract][Full Text] [Related]
60. [Lipoprotein(a) as a biochemical marker of coronary atherosclerosis].
Ezhov MV; Afanas'ev OI; Benevolenskaia GF; Savchenko AP; Liakishev AA; Pokrovskiĭ SN
Ter Arkh; 1997; 69(9):31-4. PubMed ID: 9411822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
